1. Generics Bulletin
  2. >>Business

Biomm Backs Bio-Thera’s Brazilian Bevacizumab

Marketing Deal Follows Global Filings And Partnerships For Avastin Biosimilar

 
• By Dave Wallace

China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.

Brazil China Flags Jigsaw
China’s Bio-Thera sets its sights on Brazil with Biomm • Source: Shutterstock

China’s Bio-Thera Solutions has struck a licensing deal with Brazil’s Biomm that will give the Brazilian firm exclusive rights to market Bio-Thera’s BAT1706 proposed biosimilar version of Avastin (bevacizumab) in its domestic market.

“Biomm will have exclusive rights to distribute and market the drug in Brazil,” the Chinese company confirmed, indicating that Biomm would also

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.